Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) had its target price hoisted by equities research analysts at HC Wainwright from $25.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 152.95% from the stock’s previous close. HC Wainwright also issued estimates for Deciphera Pharmaceuticals’ Q1 2024 earnings at ($0.64) EPS, Q2 2024 earnings at ($0.67) EPS, Q3 2024 earnings at ($0.68) EPS and Q4 2024 earnings at ($0.62) EPS.
Several other analysts have also issued reports on the stock. Stifel Nicolaus upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $14.00 to $20.00 in a research report on Wednesday, August 9th. Piper Sandler upgraded Deciphera Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $23.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.63.
Read Our Latest Report on Deciphera Pharmaceuticals
Deciphera Pharmaceuticals Stock Down 1.1 %
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Free Report) last posted its earnings results on Monday, October 30th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.03. The business had revenue of $43.31 million during the quarter, compared to the consensus estimate of $39.66 million. Deciphera Pharmaceuticals had a negative net margin of 127.92% and a negative return on equity of 48.99%. During the same quarter in the previous year, the firm posted ($0.55) EPS. Analysts anticipate that Deciphera Pharmaceuticals will post -2.36 earnings per share for the current year.
Insider Buying and Selling
In other news, EVP Matthew L. Sherman sold 2,360 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $12.02, for a total transaction of $28,367.20. Following the sale, the executive vice president now owns 90,628 shares in the company, valued at $1,089,348.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Matthew L. Sherman sold 2,942 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $12.68, for a total value of $37,304.56. Following the completion of the transaction, the executive vice president now directly owns 84,744 shares of the company’s stock, valued at $1,074,553.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Matthew L. Sherman sold 2,360 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $12.02, for a total transaction of $28,367.20. Following the sale, the executive vice president now directly owns 90,628 shares in the company, valued at approximately $1,089,348.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,598 shares of company stock valued at $369,730. Corporate insiders own 4.43% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in DCPH. BlackRock Inc. increased its stake in Deciphera Pharmaceuticals by 2.3% during the first quarter. BlackRock Inc. now owns 5,544,988 shares of the company’s stock worth $85,670,000 after acquiring an additional 124,963 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Deciphera Pharmaceuticals by 9.2% in the third quarter. Vanguard Group Inc. now owns 4,794,993 shares of the company’s stock valued at $88,708,000 after acquiring an additional 402,047 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 356.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 3,663,819 shares of the company’s stock worth $48,179,000 after acquiring an additional 2,861,642 shares during the last quarter. Braidwell LP boosted its stake in shares of Deciphera Pharmaceuticals by 12.5% during the 2nd quarter. Braidwell LP now owns 3,646,419 shares of the company’s stock worth $51,342,000 after purchasing an additional 405,068 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Deciphera Pharmaceuticals by 125.5% during the 1st quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company’s stock valued at $18,161,000 after purchasing an additional 1,090,368 shares during the last quarter. Institutional investors own 70.96% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Featured Articles
- Five stocks we like better than Deciphera Pharmaceuticals
- Transportation Stocks Investing
- First Solar, an affordable, high-quality green investment
- 3 Healthcare Dividend Stocks to Buy
- 5 Dow stocks to track during the market correction
- What to Know About Investing in Penny Stocks
- Lean on these stocks during GDP expansion
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
